>>Signaling Pathways>> Metabolism>> Phospholipase>>ML 349

ML 349

Catalog No.GC17889

ML 349는 Ki가 120nM인 강력하고 특이적 아실 단백질 티오에스테라제 2(APT2)/리소포스포리파제 2(LYPLA2) 억제제입니다. ML 349는 또한 IC50이 144nM인 LYPLA2의 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

ML 349 Chemical Structure

Cas No.: 890819-86-0

Size 가격 재고 수량
1mg
US$35.00
재고 있음
5mg
US$105.00
재고 있음
10mg
US$194.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

ML349 is a potent and specific acyl protein thioesterase 2 (APT-2) inhibitor with a Ki of 120 nM. ML349 is also an inhibitor of LYPLA2 with an IC50 of 144 nM.

ML349 is an inhibitor of acyl protein thioesterase 1 and 2 (APT-1 and APT-2) with Kis of >10000 and 120±20 nM, respectively[1]. ML349 is also an inhibitor of both LYPLA1 and LYPLA2 with IC50s of >3000 and 144 nM, respectivley[2]. ML348 and ML349 do not decrease cell viability, but they lead to a slight activation of AKT in NRAS mutant cells[3].

References:
[1]. Won SJ, et al. Molecular Mechanism for Isoform-Selective Inhibition of Acyl Protein Thioesterases 1 and 2 (APT1 and APT2). ACS Chem Biol. 2016 Dec 16;11(12):3374-3382.
[2]. Adibekian A, et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2).
[3]. Vujic I, et al. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget. 2016 Feb 9;7(6):7297-306.

리뷰

Review for ML 349

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ML 349

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.